Happy Friday Zingernation! Sometimes you need to learn a lesson the hard way. Like when I tried to take a quick 15-minute nap while my frozen pizza was in the oven (spoiler alert: I slept for longer than 15 minutes). Robinhood apparently learned its lesson after the 2021 $GME short squeeze and says it’s prepared for anything today.

—Aaron Bry & Nic Chahine

Plus, take a look at the med-tech company that’s aiming to pioneer the industry through cutting-edge technology.

MARKET SNAPSHOT

Yesterday: A relatively flat day yesterday, with the S&P 500 and Nasdaq closing slightly red while the Dow closed higher.

On Our Radar: Labor data! U.S. unemployment rate and the employment report will come out at 8:30 am ET.

TOP STORY

GameStop Releases Q1 Results Ahead Of 'Roaring Kitty' Event, Files Prospectus To Raise Capital Via Equity Offering

Briefly: Video game retailer GameStop stock released its first-quarter 2024 results ahead of its scheduled June 11.

So: The company reported net sales of $881.80 million, down from $1.237 billion year-over-year. The net sales total missed a consensus estimate of $995.30 million.

The Numbers: The company reported an EPS loss of $(0.12), missing the estimate of $(0.09). The gross margin improved by 450 bps to 27.7%. The quarter’s net loss was $(32.3) million, down from $(50.5) million last year.

Why It Matters: The performance reflects customer’s transition to video games and collectibles online, while the retailer depended on brick-and-mortar stores, Reuters reports.

Click here to read more. 

PRESENTED BY AUTONOMIX

The Full Opportunity: Autonomix’s Ability To Address A Number Of Multi-Billion Dollar Blockbuster Indications

Autonomix Medical (NASDAQ: AMIX) is a pioneering medical device company dedicated to transforming the diagnosis and treatment of diseases related to the autonomic nervous system. At the core of Autonomix's innovative approach is a first-in-class technology platform featuring a catheter-based microchip sensing array.

This technology boasts an unprecedented ability to detect and differentiate neural signals with up to 3,000 times greater sensitivity than existing technologies. This breakthrough has paved the way for transvascular diagnosis and treatment of peripheral nervous system (PNS) diseases virtually anywhere in the body, offering a new horizon of medical possibilities and market opportunities.

This opens up multiple multi-billion dollar markets for the company, including chronic pain, cardiovascular disease and pulmonary disease. The company has already initiated In-Human trials for its treatment for pancreatic cancer pain as a proof-of-concept.

Click here to read more.

FIVE ZINGERS

Mailbox Money: Dividend stocks are a great way to collect money while doing absolutely nothing. And here are the ones that analysts love.

Second Place: Experts say that the interest in upcoming Ethereum ETFs may be muted compared to the traction in Bitcoin ETFs.

Who You Gonna Call: Stock busters! The Justice Department and FTC are apparently looking into $MSFT, Open AI and $NVDA on antitrust claims.

Hertz, Don’t It?: Hertz closed down more than 4% yesterday after reports that the car-rental company is looking for a $700-million lifeline.

Plan Ahead: The recommended retirement savings amount is $550K, so why are so many Americans are falling short?

ONE FOR THE ROAD

Strategist Explains How Nvidia Options Traders Should Position Themselves Ahead Of Friday's Stock Split

Briefly: NVIDIA shares retreated on Thursday after the company’s market cap breached the $3 trillion mark in the previous session. An options strategist delved into the volatility seen in the stock ahead of the imminent split.

What Happened: Nvidia options are priced extraordinarily high with a stock price over $1000 and 50% implied volatility, said Matt Amberson, founder of Option Research & Technology Services, in an interview with Yahoo Finance.

Quoted: “Options traders are really looking forward to the split,” the strategist said, adding that it will help them trade it a lot easier without the $1,200 price tag.

So: The beta of Nvidia is 1.7, which suggests the stock would outperform when the market goes higher and underperform when the reverse happens, Amberson said. Options traders could profit from not being short but being long spread so that traders can do this way out of the money spreads, he said.

The Trade: A long spread gives traders the right to buy stock at strike price A and obligates them to sell the stock at strike price B if assigned. Selling a cheaper call with a higher-strike B helps to offset the cost of the call bought at strike A.

Click here for the full trade breakdown.

PRESENTED BY AUTONOMIX

The Full Opportunity: Autonomix’s Ability To Address A Number Of Multi-Billion Dollar Blockbuster Indications

Autonomix Medical (NASDAQ: AMIX) is a pioneering medical device company dedicated to transforming the diagnosis and treatment of diseases related to the autonomic nervous system. At the core of Autonomix's innovative approach is a first-in-class technology platform featuring a catheter-based microchip sensing array.

This technology boasts an unprecedented ability to detect and differentiate neural signals with up to 3,000 times greater sensitivity than existing technologies. This breakthrough has paved the way for transvascular diagnosis and treatment of peripheral nervous system (PNS) diseases virtually anywhere in the body, offering a new horizon of medical possibilities and market opportunities.

This opens up multiple multi-billion dollar markets for the company, including chronic pain, cardiovascular disease and pulmonary disease. The company has already initiated In-Human trials for its treatment for pancreatic cancer pain as a proof-of-concept.

Click here to read more.

BEFORE YOU GO

Were you forwarded this email? Click here to subscribe.

And be sure to check out our other newsletters:

Future Finance: Where fintech, crypto, and the future of finance collide. Future Finance is a perfect lunch read packed with quick bites for industry enthusiasts. Subscribe here.

Cannabis Daily: A must-read daily briefing for cannabis investors, operators, and enthusiasts. Join our list of industry veterans to jump start your morning. Subscribe here.

Real Estate Weekly: Where we highlight the movers and the losers, the upgrades and the downgrades, the top stories and opportunities in the trillion dollar REIT and real asset industry. Subscribe here.

Mining Weekly: Get an insider's edge with news, analysis, and commentary on what’s shaping the mining and commodities industry that powers the global economy. Subscribe here.